These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

589 related items for PubMed ID: 26961276

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
    Gupta V, Baabbad R, Hammerby E, Nikolajsen A, Shafie AA.
    J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M, Azoulay M, Greiner RA.
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
    Brändle M, Azoulay M, Greiner RA.
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
    [Abstract] [Full Text] [Related]

  • 8. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.
    Valentine WJ, Erny-Albrecht KM, Ray JA, Roze S, Cobden D, Palmer AJ.
    Adv Ther; 2007 Apr; 24(2):273-90. PubMed ID: 17565917
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes.
    Valentine WJ, Goodall G, Aagren M, Nielsen S, Palmer AJ, Erny-Albrecht K.
    Adv Ther; 2008 Jun; 25(6):567-84. PubMed ID: 18568451
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Cost-Utility Analysis.
    Dawoud D, Fenu E, Higgins B, Wonderling D, Amiel SA.
    Value Health; 2017 Dec; 20(10):1279-1287. PubMed ID: 29241887
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
    Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T.
    Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
    [Abstract] [Full Text] [Related]

  • 16. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.
    Grima DT, Thompson MF, Sauriol L.
    Pharmacoeconomics; 2007 Apr; 25(3):253-66. PubMed ID: 17335310
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH.
    Valentine WJ, Palmer AJ, Erny-Albrecht KM, Ray JA, Cobden D, Foos V, Lurati FM, Roze S.
    Adv Ther; 2006 Apr; 23(2):191-207. PubMed ID: 16751153
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.